Nightingale Health: Seeking a commercial recipe for success
Nightingale Health is a technology company built around blood analysis. The company tries with new technology, which initially seems competitive, to break into a conservative health care customer base, where achieving commercial success and its possible timing are, however, very uncertain. Despite the high long-term potential, we still have to wait for the signs of success and believe that positive share price drivers are still scarce. We, therefore, believe that the risk/return ratio will be weak over the next 12 months.
Login required
This content is only available for logged in users
Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.
Read more on company pageKey Estimate Figures05.06.2023
| 2022 | 23e | 24e | |
|---|---|---|---|
| Revenue | 2.3 | 4.3 | 5.2 |
| growth-% | 0.3 % | 84.2 % | 22.2 % |
| EBIT (adj.) | -13.6 | -18.4 | -17.8 |
| EBIT-% (adj.) | -589.5 % | -431.1 % | -342.5 % |
| EPS (adj.) | -0.23 | -0.30 | -0.30 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | 3.1 | 1.9 | 0.3 |
Forum discussions
